Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial

Eli Lilly stock rises on striking 23% weight loss in drug combo trial By Investing.com

Eli Lilly stock rises on striking 23% weight loss in drug combo trial

Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.

The company is working on an experimental amylin drug to see if it can help people lose weight and manage their diabetes — much like a GLP-1.

Lilly Drug Combo Spurs Record Weight Loss in Diabetes Study

Eli Lilly & Co. said a new drug combination helped people with diabetes lose as much as 23% of their weight, more than other medicines in similar studies, suggesting it has the potential to be the drugmaker’s strongest obesity shot to date.

Experimental Lilly combination drug tops Zepbound in weight-loss trial

Eli Lilly said on Wednesday its experimental combination weight-loss drug outperformed its ​blockbuster Zepbound in a head-to-head trial, intensifying the competition with Danish rival Novo Nordisk for new, more effective obesity therapies.

Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial

Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.

Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial

An investigational combination therapy from Eli Lilly led to significant weight loss in a mid-stage study, but high discontinuation rates raise questions about tolerability.